Literature DB >> 26150910

Pleural mesothelial cells in pleural and lung diseases.

Hitesh Batra1, Veena B Antony1.   

Abstract

During development, the mesoderm maintains a complex relationship with the developing endoderm giving rise to the mature lung. Pleural mesothelial cells (PMCs) derived from the mesoderm play a key role during the development of the lung. The pleural mesothelium differentiates to give rise to the endothelium and smooth muscle cells via epithelial-to-mesenchymal transition (EMT). An aberrant recapitulation of such developmental pathways can play an important role in the pathogenesis of disease processes such as idiopathic pulmonary fibrosis (IPF). The PMC is the central component of the immune responses of the pleura. When exposed to noxious stimuli, it demonstrates innate immune responses such as Toll-like receptor (TLR) recognition of pathogen associated molecular patterns as well as causes the release of several cytokines to activate adaptive immune responses. Development of pleural effusions occurs due to an imbalance in the dynamic interaction between junctional proteins, n-cadherin and β-catenin, and phosphorylation of adherens junctions between PMCs, which is caused in part by vascular endothelial growth factor (VEGF) released by PMCs. PMCs play an important role in defense mechanisms against bacterial and mycobacterial pleural infections, and in pathogenesis of malignant pleural effusion, asbestos related pleural disease and malignant pleural mesothelioma. PMCs also play a key role in the resolution of inflammation, which can occur with or without fibrosis. Fibrosis occurs as a result of disordered fibrin turnover and due to the effects of cytokines such as transforming growth factor-β, platelet-derived growth factor (PDGF), and basic fibroblast growth factor; which are released by PMCs. Recent studies have demonstrated a role for PMCs in the pathogenesis of IPF suggesting their potential as a cellular biomarker of disease activity and as a possible therapeutic target. Pleural-based therapies targeting PMCs for treatment of IPF and other lung diseases need further exploration.

Entities:  

Keywords:  Pleural mesothelium1; Wilms tumor-1 (WT1); epithelial-mesenchymal transition (EMT); idiopathic pulmonary fibrosis (IPF); pleural mesothelial cells (PMCs)

Year:  2015        PMID: 26150910      PMCID: PMC4466423          DOI: 10.3978/j.issn.2072-1439.2015.02.19

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


  215 in total

1.  Antiapoptotic function of 17AA(+)WT1 (Wilms' tumor gene) isoforms on the intrinsic apoptosis pathway.

Authors:  K Ito; Y Oji; N Tatsumi; S Shimizu; Y Kanai; T Nakazawa; M Asada; T Jomgeow; S Aoyagi; Y Nakano; H Tamaki; N Sakaguchi; T Shirakata; S Nishida; M Kawakami; A Tsuboi; Y Oka; Y Tsujimoto; H Sugiyama
Journal:  Oncogene       Date:  2006-03-06       Impact factor: 9.867

2.  Inhibition of the met receptor in mesothelioma.

Authors:  Toru Mukohara; Gabriel Civiello; Ian J Davis; Michele L Taffaro; James Christensen; David E Fisher; Bruce E Johnson; Pasi A Jänne
Journal:  Clin Cancer Res       Date:  2005-11-15       Impact factor: 12.531

Review 3.  Innate immunity: impact on the adaptive immune response.

Authors:  R Medzhitov; C A Janeway
Journal:  Curr Opin Immunol       Date:  1997-02       Impact factor: 7.486

4.  Angiogenesis in mesotheliomas. Role of mesothelial cell derived IL-8.

Authors:  V B Antony; J W Hott; S W Godbey; K Holm
Journal:  Chest       Date:  1996-03       Impact factor: 9.410

5.  HGF reduces advancing lung fibrosis in mice: a potential role for MMP-dependent myofibroblast apoptosis.

Authors:  Shinya Mizuno; Kunio Matsumoto; Ming-Yue Li; Toshikazu Nakamura
Journal:  FASEB J       Date:  2005-01-21       Impact factor: 5.191

6.  Aberrant Wnt/beta-catenin pathway activation in idiopathic pulmonary fibrosis.

Authors:  Marco Chilosi; Venerino Poletti; Alberto Zamò; Maurizio Lestani; Licia Montagna; Paola Piccoli; Serena Pedron; Manuela Bertaso; Aldo Scarpa; Bruno Murer; Alessandra Cancellieri; Roberta Maestro; Gianpietro Semenzato; Claudio Doglioni
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

7.  Presence of elevated levels of platelet-derived growth factor (PDGF) in lung adenocarcinoma pleural effusions.

Authors:  A Safi; M Sadmi; N Martinet; O Menard; P Vaillant; H Gallati; M Hosang; Y Martinet
Journal:  Chest       Date:  1992-07       Impact factor: 9.410

8.  PDGF-A signaling is a critical event in lung alveolar myofibroblast development and alveogenesis.

Authors:  H Boström; K Willetts; M Pekny; P Levéen; P Lindahl; H Hedstrand; M Pekna; M Hellström; S Gebre-Medhin; M Schalling; M Nilsson; S Kurland; J Törnell; J K Heath; C Betsholtz
Journal:  Cell       Date:  1996-06-14       Impact factor: 41.582

9.  Overexpression of the Wilms' tumor gene WT1 in de novo lung cancers.

Authors:  Yusuke Oji; Shinichiro Miyoshi; Hajime Maeda; Seiji Hayashi; Hiroya Tamaki; Shin-Ichi Nakatsuka; Masayuki Yao; Eigo Takahashi; Yoko Nakano; Hirohisa Hirabayashi; Yasushi Shintani; Yoshihiro Oka; Akihiro Tsuboi; Naoki Hosen; Momotaro Asada; Tatsuya Fujioka; Masaki Murakami; Keisuke Kanato; Mari Motomura; Eui Ho Kim; Manabu Kawakami; Kazuhiro Ikegame; Hiroyasu Ogawa; Katsuyuki Aozasa; Ichiro Kawase; Haruo Sugiyama
Journal:  Int J Cancer       Date:  2002-07-20       Impact factor: 7.396

10.  Mycobacteria induces pleural mesothelial permeability by down-regulating beta-catenin expression.

Authors:  K A Mohammed; N Nasreen; J Hardwick; R D Van Horn; K L Sanders; V B Antony
Journal:  Lung       Date:  2003       Impact factor: 2.584

View more
  28 in total

1.  Advances and controversies in pleural diseases.

Authors:  José M Porcel; Georgios Statophoulos; Yun Chor Gary Lee
Journal:  J Thorac Dis       Date:  2015-06       Impact factor: 2.895

Review 2.  Making cold malignant pleural effusions hot: driving novel immunotherapies.

Authors:  Pranav Murthy; Chigozirim N Ekeke; Kira L Russell; Samuel C Butler; Yue Wang; James D Luketich; Adam C Soloff; Rajeev Dhupar; Michael T Lotze
Journal:  Oncoimmunology       Date:  2019-01-22       Impact factor: 8.110

3.  Ezh2 restricts the smooth muscle lineage during mouse lung mesothelial development.

Authors:  Melinda Snitow; MinMin Lu; Lan Cheng; Su Zhou; Edward E Morrisey
Journal:  Development       Date:  2016-08-30       Impact factor: 6.868

4.  miR-18a-5p Inhibits Sub-pleural Pulmonary Fibrosis by Targeting TGF-β Receptor II.

Authors:  Qian Zhang; Hong Ye; Fei Xiang; Lin-Jie Song; Li-Ling Zhou; Peng-Cheng Cai; Jian-Chu Zhang; Fan Yu; Huan-Zhong Shi; Yunchao Su; Jian-Bao Xin; Wan-Li Ma
Journal:  Mol Ther       Date:  2017-01-26       Impact factor: 11.454

5.  Myocardin Is Involved in Mesothelial-Mesenchymal Transition of Human Pleural Mesothelial Cells.

Authors:  Torry Tucker; Yoshikazu Tsukasaki; Tsuyoshi Sakai; Shinya Mitsuhashi; Satoshi Komatsu; Ann Jeffers; Steven Idell; Mitsuo Ikebe
Journal:  Am J Respir Cell Mol Biol       Date:  2019-07       Impact factor: 6.914

Review 6.  Elastin in lung development and disease pathogenesis.

Authors:  Robert P Mecham
Journal:  Matrix Biol       Date:  2018-01-11       Impact factor: 11.583

7.  Identification of a FGF18-expressing alveolar myofibroblast that is developmentally cleared during alveologenesis.

Authors:  Andrew S Hagan; Bo Zhang; David M Ornitz
Journal:  Development       Date:  2020-01-17       Impact factor: 6.868

Review 8.  Sterile Injury Repair and Adhesion Formation at Serosal Surfaces.

Authors:  Simone N Zwicky; Deborah Stroka; Joel Zindel
Journal:  Front Immunol       Date:  2021-05-14       Impact factor: 7.561

Review 9.  Malignant Pleural Effusions-A Window Into Local Anti-Tumor T Cell Immunity?

Authors:  Nicola Principe; Joel Kidman; Richard A Lake; Willem Joost Lesterhuis; Anna K Nowak; Alison M McDonnell; Jonathan Chee
Journal:  Front Oncol       Date:  2021-04-27       Impact factor: 6.244

10.  Anaphylatoxins orchestrate Th17 response via interactions between CD16+ monocytes and pleural mesothelial cells in tuberculous pleural effusion.

Authors:  Shuanglinzi Deng; Xinyue Hu; Lisha Luo; Wei Tang; Yuanyuan Jiang; Feifei Yin; Chengping Hu; Juntao Feng; Xiaozhao Li
Journal:  PLoS Negl Trop Dis       Date:  2021-07-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.